Nurix Therapeutics Inc.
NRIX | NASDAQ
$25.41
-$0.03 (-0.12%)
At close: Sep 21, 2026, 4:00 PM ET
$25.40
-$0.01 (-0.04%)
Pre-market:
Sep 22, 2026, 5:28 AM ET
Fiscal Year Period Ending | FY 2025 Nov 29, 2025 | FY 2024 Nov 29, 2024 | FY 2023 Nov 29, 2023 | FY 2022 Nov 29, 2022 | FY 2021 Nov 29, 2021 | FY 2020 Nov 29, 2020 |
|---|---|---|---|---|---|---|
Revenue | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M | 17.82M |
Cost of Revenue | 18.86M | 221.63M | 189.15M | 184.5M | 116.43M | 66.49M |
Gross Profit | 65.12M | -167.08M | -112.16M | -145.87M | -86.68M | -48.67M |
Operating Income | -285.67M | -213.03M | -155.06M | -183.87M | -117.89M | -64.98M |
Interest Income | 21.97M | 19.73M | 11.12M | 3.51M | 823K | 1.21M |
Pretax Income | -263.7M | -193.3M | -143.95M | -180.36M | -117.06M | -63.78M |
Net Income | -264.46M | -193.57M | -143.95M | -180.36M | -117.19M | -43.24M |
Selling & General & Admin | 52.74M | 45.94M | 42.9M | 38M | 31.2M | 16.31M |
Research & Development | 308.16M | 221.63M | 189.15M | 184.5M | 116.43M | 66.49M |
Other Expenses | -10.12M | -221.63M | -189.15M | -184.5M | -116.43M | -66.49M |
Operating Expenses | 350.79M | 45.94M | 42.9M | 38M | 31.2M | 16.31M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 369.65M | 267.58M | 232.05M | 222.49M | 147.64M | 82.8M |
Income Tax Expense | 760K | 270K | n/a | n/a | 131K | -20.54M |
Shares Outstanding (Basic) | 86.67M | 67.12M | 54.34M | 48.61M | 42.9M | 15.67M |
Shares Outstanding (Diluted) | 86.67M | 67.12M | 54.34M | 48.61M | 42.9M | 15.67M |
EPS (Basic) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 |
EPS (Diluted) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 |
EBITDA | -244.84M | -185.28M | -137.82M | -176.21M | -115.07M | -62.8M |
EBIT | -263.7M | -193.3M | -143.95M | -180.36M | -117.06M | -64.98M |
Depreciation & Amortization | 18.86M | 8.02M | 6.13M | 4.15M | 1.99M | 2.18M |
Add to Watchlist
Select watchlists to add or remove NRIX